About GW Pharmaceuticals (NASDAQ:GWPH)
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800
Debt
Debt-to-Equity Ratio0.01%
Current Ratio11.44%
Quick Ratio11.34%
Price-To-Earnings
Trailing P/E Ratio-19.05
Forward P/E Ratio-13.71
P/E GrowthN/A
Sales & Book Value
Annual Sales$11 million
Price / Sales334.33
Cash FlowN/A
Price / CashN/A
Book Value$13.92 per share
Price / Book9.51
Profitability
EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,357.98%
Return on Equity-46.94%
Return on Assets-41.00%
Miscellaneous
Employees583
Outstanding Shares27,770,000
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."
How were GW Pharmaceuticals' earnings last quarter?
GW Pharmaceuticals (NASDAQ:GWPH) issued its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.03) by $0.40. The biopharmaceutical company earned $7.73 million during the quarter, compared to analyst estimates of $2.18 million. GW Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. View GW Pharmaceuticals' Earnings History.
When is GW Pharmaceuticals' next earnings date?
What price target have analysts set for GWPH?
7 brokerages have issued 1-year price targets for GW Pharmaceuticals' stock. Their predictions range from $61.00 to $205.00. On average, they expect GW Pharmaceuticals' share price to reach $152.1429 in the next year. View Analyst Ratings for GW Pharmaceuticals.
What are Wall Street analysts saying about GW Pharmaceuticals stock?
Here are some recent quotes from research analysts about GW Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (3/21/2018)
- 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)
Who are some of GW Pharmaceuticals' key competitors?
Some companies that are related to GW Pharmaceuticals include Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY) and Tesaro (TSRO).
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the folowing people:
- Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
- Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
- Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
- Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
- Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)
Has GW Pharmaceuticals been receiving favorable news coverage?
Headlines about GWPH stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals earned a news impact score of 0.19 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of GW Pharmaceuticals?
Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GW Pharmaceuticals' stock price today?
One share of GWPH stock can currently be purchased for approximately $132.43.
How big of a company is GW Pharmaceuticals?
GW Pharmaceuticals has a market capitalization of $3.72 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals employs 583 workers across the globe.
How can I contact GW Pharmaceuticals?
GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]
MarketBeat Community Rating for GW Pharmaceuticals (GWPH)
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
GW Pharmaceuticals (NASDAQ:GWPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for GW Pharmaceuticals in the last 12 months. Their average twelve-month price target is $152.1429, suggesting that the stock has a possible upside of 14.89%. The high price target for GWPH is $205.00 and the low price target for GWPH is $61.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.88 | 2.71 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $152.1429 | $150.2857 | $152.50 | $144.5714 |
| Price Target Upside: | 14.89% upside | 13.57% upside | 23.00% upside | 26.18% upside |
GW Pharmaceuticals (NASDAQ:GWPH) Consensus Price Target History
GW Pharmaceuticals (NASDAQ:GWPH) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
GW Pharmaceuticals (NASDAQ:GWPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GW Pharmaceuticals (NASDAQ GWPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 82.50%
GW Pharmaceuticals (NASDAQ GWPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
GW Pharmaceuticals (NASDAQ GWPH) News Headlines
| Source: |
|
GW Pharmaceuticals (NASDAQ:GWPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GW Pharmaceuticals (NASDAQ:GWPH) Income Statement, Balance Sheet and Cash Flow Statement
GW Pharmaceuticals (NASDAQ GWPH) Stock Chart for Sunday, April, 22, 2018
Loading chart…
